Key Players Covered in the Long Term Care Technology Market Research Report Are Medline Industries Inc. (U.S.), Medtronic (Ireland), B. Braun Melsungen AG (Germany), 3M (U.S.), Baxter (U.S.), ARKRAY Inc. (Japan), BD (U.S.), Omron Healthcare Inc. (Japan), Koninklijke Philips N.V. (Netherlands), GENERAL ELECTRIC COMPANY (U.S.), Fresenius Medical Care AG & Co. KGaA (Germany), Cardinal Health (U.S.), Boston Scientific Corporation (U.S.), Honeywell International Inc. (U.S.) and other key market players.
Pune, India, Dec. 20, 2021 (GLOBE NEWSWIRE) — The global long term care technology market size is expected to witness an elevated market growth owing to increasing collaboration between private insurers and various government bodies. This information is provided by Fortune Business Insights™, in its report, titled, “Long Term Care Technology Market, 2021-2028.” Additionally, increased life expectancy among disability cases and rising demand from post-op surgeries will fuel the growth of the market.
November 2019: OMRON Healthcare Inc. was recently acknowledged as one of the recipients for the Best Inventions 2019 for their HeartGuide™. HeartGuide™ is one of its kind wearable blood pressure monitoring devices.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/long-term-care-technology-market-104469
Drivers & Restraints
Rising Geriatric Population to Accelerate Growth During the Forecast Duration
Increasing chronic diseases and rising aging population will bolster the long term care technology market growth. Also, shortage of nursing professionals and rising prevalence of diabetes will increase the footprint of the market. Rocketing government subsidiaries and increased cooperation between private insurers and government providers will expand the market growth.
However, lack of awareness and lower access potency is expected to hamper the market growth to a certain extent. Lower rate of compensation among insurance providers will hinder the market growth during the forecast duration.
Click here to get the short-term and long-term impact of COVID-19 on this market.
Please visit: https://www.fortunebusinessinsights.com/long-term-care-technology-market-104469
North America to Dominate Market Due to Accelerated Regulatory Framework
Geographically, North America is expected to dominate the market worldwide. Factors such as rising geriatric population and streamlined regulatory framework will aid growth in the upcoming year.
Asia Pacific will hold the fastest growing market during the forecast duration owing to increasing and rising incidences of chronic diseases such as cardiac disorders, diabetes, and other conditions. Also, the ever increasing population and an undersupply of healthcare facilities in countries like India will boost the long term care technology market share in the region.
Europe is expected to occupy a substantial market share due to rising healthcare expenditure, increasing geriatric population, and a rocketing rate of chronic diseases. Also, rising number of healthcare facilities and increased utilization of LTC technology will bolster the growth of the market.
Order Full Report: https://www.fortunebusinessinsights.com/checkout-page/104469
On the basis of type, the market can be divided into software, equipment, therapeutics, and diagnostics.
By end users, the market can be broken down into hospitals, nursing homes, home care settings, and others.
In terms of region, the market can be differentiated into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
Dominant Players Focus on Hastening Approvals and New Product Launches in Order to Compete with Counterparts
The global market for long term care technology is occupied by a huge number of prominent players that are currently focused on launching the most innovative products for their patients. A few others are trying to get approval from regulatory bodies in order to distribute their products towards a wider range of consumers. For example, in October 2019, 3M announced the acquisition of Acelity Inc. which was aimed at delivering safe and effective solutions for improving clinical outcomes in order to improve healthcare aesthetics. A small portion of key players are also focused on developing cutting edge technology in order to outbid their competitors.
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/customization/long-term-care-technology-market-104469
List of Key Players Present in the Market
Medline Industries Inc. (U.S.)
B. Braun Melsungen AG (Germany)
ARKRAY Inc. (Japan)
Omron Healthcare Inc. (Japan)
Koninklijke Philips N.V. (Netherlands)
GENERAL ELECTRIC COMPANY (U.S.)
Fresenius Medical Care AG & Co. KGaA (Germany)
Cardinal Health (U.S.)
Boston Scientific Corporation (U.S.)
Honeywell International Inc. (U.S.)
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Stock picker and hedge manager Cathie Wood made some serious waves last year, when her ARK Innovation ETF outperformed the S&P 500 by an order of magnitude. From the pandemic trough in March to the end of 2020, the S&P gained 68%, while Wood’s flagship fund surged ahead by 153%. It was an astounding performance. Wood made smart choices last year, targeting tech companies, remote connections, and telehealth for investment. All of those segments saw big gains in business during the lockdown phases
In this article, we’ll discuss Jim Cramer’s most favorite tech stocks to buy now. You can skip our detailed analysis of Cramer’s background and tech stocks, and go directly to read Jim Cramer’s 5 Most Favorite Tech Stocks to Buy Now. Jim Cramer is one of the most prominent names in the investment world. His […]
Shares of Nio (NYSE: NIO) set their all-time high back on Jan. 11, when they traded at $66.99 at some point during the day. Clearly it has been a rough year for Nio, which has been hit by COVID-19 shutdowns, supply chain challenges, and a lull in its new-product cycle that allowed competitors to gain ground. Nio will begin shipping its long-awaited ET7 sedan in March, followed in September by the one-size-down ET5, which was revealed on Saturday. Meanwhile, its order books remain strong, its customer satisfaction is high, and there are signs that it may have put the worst of the supply chain woes in the rearview mirror.
The folks at Bespoke say the day after an ugly Monday selloff, with drops of at least 1%, tend to be followed by a comparatively strong Tuesday performance.
Bank of America unveiled its top stocks for next year among the 11 S&P 500 sectors. But its track record isn't great.
Shares of fintech leader Block (NYSE: SQ) — the artist formerly known as Square — dropped in Monday morning trading. You can blame investment bank Wedbush for that. Coronavirus worries are tanking the stock market this morning, and coronavirus worries make up a big part of why Wedbush just cut its price target on Block stock by 24%, to $190 a share.
AT&T Inc. (NYSE:T) was a rare outperformer last week after Morgan Stanley analyst Simon Flannery upgraded his rating on the stock from ‘equal-weight’ to overweight. The stock gained 6.95% on Thursday, its biggest one day gain in months – although the stock price is still down nearly 20% for the year. Flannery said price weakness had created an opportunity and upgraded his rating, though he lowered the price target from $32 to $28.
Here are three growth stocks that will skyrocket 50% or more in 2022, according to Wall Street. The consensus 12-month price target for Sea Limited (NYSE: SE) reflects an upside potential of 89%. Sea's past success has been primarily driven by its Free Fire mobile game.
(Bloomberg) — China slapped an unprecedented $210 million fine on a top livestreamer for tax evasion, stepping up President Xi Jinping’s crackdown on online influencers who have grown wildly popular in recent years.Most Read from BloombergModerna’s Third Dose Boosts Antibodies Against OmicronS&P 500 Has Biggest Three-Day Drop Since September: Markets WrapBilly Joel NYC Show Going Ahead; Quebec Closures: Virus UpdateOmicron Becomes Dominant U.S. Strain With 73% of Covid CasesManchin Outlines Tax
Shares of Chilean lithium mining stock Sociedad Quimica y Minera (NYSE: SQM) melted down on Monday, down 13% as of 10:30 a.m. ET. You can blame Bank of America for that — and the voters of the nation of Chile. Yesterday, in a historic upset, former Chilean student activist Gabriel Boric was elected Chile's new president — and at just 35 years of age, the youngest and least experienced president in Chilean history.
Vaccine stocks Moderna and Novavax fell Monday despite bullish news for their Covid vaccines as omicron cases continue rising.
While there's no way to know for sure if a given stock has what it takes to outperform, looking at a company's upcoming catalysts is one trick that can help to stack the deck in your favor. Catalyst Pharmaceuticals (NASDAQ: CPRX) makes a drug called Firdapse for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. Since the drug's first sales in 2019, the company's quarterly revenue has exploded by a shocking 7,090%.
Rivian (RIVN) stock has had quite a ride since going public, increasing 61% before crashing back down whilst shedding 46% of its value. The drop came on account of the company’s first earnings report as a public entity. Rivian delivered 11 R1Ts in the quarter which resulted in total revenue of about $1 million. The company's lofty valuation, however, has less to do with present sales and is based on the electric truck startup’s promise. Here the Street appeared disappointed to learn of a slower-
FEATURES – MAIN The U.S. stock market hasn’t followed the script in 2021. The index returned 26% through Dec. 16, well ahead of the roughly 10% gain projected, on average, by strategists at the start of the year.
These stocks are caught in a general stock market downturn, but there are also questions about the cannabis market itself.
(Bloomberg) — Cruise LLC Chief Executive Officer Dan Ammann had a slate of meetings on Dec. 16 when he got an early afternoon call from General Motors Co. CEO Mary Barra. She told Ammann he was being dismissed from the robotaxi startup that GM controls through a majority stake, say people familiar with the events.Most Read from BloombergModerna’s Third Dose Boosts Antibodies Against OmicronS&P 500 Has Biggest Three-Day Drop Since September: Markets WrapBilly Joel NYC Show Going Ahead; Quebec Cl
When stocks trade sideways, traders who are also investors can trade around a core position, extracting capital while keeping the name on the books. This is a multi-year deal – I don't see a dollar amount – that starts out as Palantir's most comprehensive partnership to date with any biotech company.
A funny thing happened after Carnival (NYSE: CCL) (NYSE: CUK) reported earnings this morning — and I mean funny strange, not actually funny. With the cruise company heading into its still-pandemic-plagued fiscal fourth quarter 2021, analysts had forecast that it would lose $1.28 per share despite taking in $1.34 billion in revenue — but it seems Carnival managed to miss on both the top and bottom lines. Revenue for the quarter was only $1.29 billion, and the company reported a generally accepted accounting principles loss of $2.31 per share.
With Nio (NIO) stock coming under almost constant pressure in 2021 (down 42% YTD), the company’s NIO Day – which took place on Saturday – had been noted as a possible catalyst to finally kick a turnaround into action. As expected, at the event, the company announced the ET7 model’s launch. Deliveries will start on March 28th; Morgan Stanley’s Tim Hsiao says the announcement will help to “alleviate investor concerns” over delayed deliveries due to supply bottlenecks. However, of more importance,
Or, with the Federal Reserve accelerating its tapering of quantitative easing and potentially raising official interest rates in 2022, is this the end of the bull run that started in early 2020? For answers, we look to the major players: “passive” investors and the Fed. Passive funds, such as exchange traded funds that invest in the S&P 500 Index (SPX) have been gaining market share for decades and are now at a critical mass of all professionally managed assets.